

Prescribing Briefing for all Lincolnshire practices on Covid-19 Response

31st March 2020

- Daily briefing will be issued at 5pm
- Will include latest national guidance, local plans, updates on actions and answers to key questions
- General queries from practices should be emailed to leccg.c19.lincsprescribing@nhs.net
Responses will be provided in the daily briefing
- Clinical forum will be established from 19 March to provide guidance regarding clinical issues, please send these to the generic email. Feedback will be provided in the daily brief.
- Local escalation/issues to be raised directly with your regular primary care team
- Additional names for the daily briefing email should be sent to the generic email address above

In today's briefing:

- | |
|--|
| 1. Lincolnshire Pharmacy Group (COVID-19) |
| 2. Optum MMO Service Update |
| 3. Optum MMO Access for Practice Support |
| 4. PACE Bulletin |
| 5. MHRA Drug Safety Update |
| 6. Medication Supply Issues |
| 7. ConvaTec – Stoma Patient Support |
| 8. Fresenius Kabi COVID-19 Update |
| 9. Contact Details |

Lincolnshire Pharmacy Group (COVID-19)

This group has been established to support pharmacy & medicines issues relating to the local COVID-19 response, both in primary and secondary care. The group is aligned to and part of the Primary Care Cell in the Lincolnshire COVID-19 response structure. The group will issue this daily update to be released alongside the general primary care bullet-in.

The group consists of a coordinator, CCG pharmacy programme team, Optum MMO team, Chief Pharmacists and the Chair of the Local Pharmaceutical Committee.

Contact details for this group as well as the primary care cell are included at the end of this briefing.

Optum MMO Service Update

The Optum MMO team have agreed with the CCG to deprioritise daily business activity and are supporting the Primary Care Cell to implement their COVID-19 response via the Lincolnshire Pharmacy Group. This includes providing daily pharmacy communication for circulation, supporting with COVID related pharmacy and medicines queries, providing expertise to the clinical COVID-19 group and attending the weekly national and regional webinars hosted by NHSE.

The following activities are on hold until further notice:

- All prescribing locality meetings planned for the next 12 weeks have been cancelled to maintain a higher level of GP availability in their practices.
- PACEF meetings – only urgent items will be circulated to members for ratification
- IMPACT educational training - Practices that were booked to receive IMPACT sessions in March will be able to reschedule them for later in the year.
- All QIPP work

Optum MMO Access for Practice Support

The Optum team have been advised to work from home wherever possible in line with the government advice.

In order to facilitate this and continue to provide practice support with COVID-19 related activity, our team will be required to have remote access and have their smart cards authorised. These agreements are in place in a large number of practices however if you have not approved this before, please can you sign the embedded document and authorise the smart cards for the people listed for your locality and return it to our inbox ohs.mmo.sharedservices@nhs.net The team will be following the Remote Access to Clinical system SOP at all times.



SL & SW remote access form.docx



LW remote access form.docx



LE remote access form.docx



OPTUM Remote Access to Clinical Sys

PACE Bulletin Vol. 14 No.3

Please find embedded the latest PACE Bulletin detailing decisions made by virtual PACEF, which includes;

- Sildenafil 25mg & 50mg tablets unlicensed use for treatment of severe Raynaud Syndrome unresponsive to first-line treatments. Approved as AMBER 2.
- InVita D3® – 800units Colecalciferol soft capsules for treatment of vitamin D deficiency. Approved as AMBER 2.
- Octasa 1600mg modified release mesalazine tablets used for treatment of mild to moderate acute ulcerative colitis. Approved as AMBER 2.
- Xaggitin XL® (methylphenidate hydrochloride) prolonged-release tablets prolonged-release tablets 18mg, 27mg, 36mg or 54mg. Used for the treatment of ADHD in children and adolescents. Approved as AMBER 1.
- Acetylcysteine 5% with Hypromellose 0.35% (Ilube®) eye drops. Approved as AMBER 2 for the treatment of corneal filaments.



PACE bulletin Vol
14 No 3 March 2020.

MHRA Drug Safety Update

Esmya- Ulipristal Acetate temporary suspension of product license due to risk of serious liver injury

The MHRA has sent out the March Drug Safety Update (copy embedded below) which alerts all clinicians to the suspension of the product license for Esmya and the recall of all products.

Esmya was licensed for the treatment of uterine fibroids.

The advice to clinicians is:

- All patients currently receiving treatment with Esmya – need to be contacted as soon as possible and advised to stop treatment.
- You will need to perform liver function tests in these patients 2-4 weeks after stopping treatment. Since August 2018 the MHRA has been recommended that LFTs are carried out on all patients after the completion of a treatment course or when treatment has been discontinued.

The Consultant Obstetrician and Gynaecologists from ULHT have confirmed that within ULHT this drug has not been prescribed and used for the last two years, since the original safety alerts were released. If a GP identifies a patient on Esmya – treatment must be stopped immediately and patients referred back to the consultant overseeing their care.

The local service has indicated they are happy to receive direct queries from GPs to discuss individual patients, if the original consultant cannot be contacted.



ulipristal-acetate-5
mg-medicinal-produ

Medication Supply Issues

Morningside Healthcare have informed us of a Vensir XL stock shortage, this product is currently our first line choice of venlafaxine MR on the Lincolnshire Joint Formulary. Messages have been temporarily muted on OptimiseRx, please consider prescribing generically until the stock issue is resolved.

ConvaTec – Stoma Patient Support

ConvaTec have provided a contact number for their Stoma Nurse Advisor line to provide Support with any Stoma enquires. The service is free of charge and open to all patients who have a Stoma.

Please share the contact number with patients and colleagues.

The number is 0800 085 2516

Fresenius Kabi COVID-19 Update

Please find embedded the latest information from Fresenius Kabi on how they are protecting their service to our patients.



Fresenius Kabi
COVID Update.docx

Contact

Important Contact Details During COVID-19 Response

For all pharmacy and prescribing issues & enquiries please email our central group inbox:

leccg.c19.lincsprescribing@nhs.net

For all issues and enquiries relating to general practice and primary care outside of pharmacy and prescribing please email the Primary Care Cell central inbox:

lincsprimary.covid19@nhs.net